Michael DiGiovanna

发表

Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).

L. Pusztai, G. Chung, A. Chagpar, 2018 .